Metabolic Drug-Drug Interactions: Perspective from FDA Medical and Clinical Pharmacology Reviewers

Advances in Pharmacology

Volumn 43, Issue C, 1997, Pages 231-238

  Balian, John Dikran ^a   Rahman, Atiqur ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DRUG APPROVAL; DRUG INTERACTION; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; METABOLISM; REVIEW; UNITED STATES;

DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0030627316     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60208-2     Document Type: Article

References (18)

1. Andersson T., Cederberg C., Edvardsson G., Heggelund A., and Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 47 (1990) 79-85
2. Andersson T., Andren K., Cederberg C., Lagerström P.-O., Lundborg P., and Skanberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br. J. Clin. Pharmacol. 29 (1990) 557-563
3. Balian J.D., Sukhova N., Harris J.W., Hewett J., Pickle L., Goldstein J.A., Woosley R.L., and Flockhart D.A. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin. Pharmacol. Ther. 57 (1995) 662-669
4. Code of Federal Regulations (1995). 21(201.57 (d) and (f-4-i)): 21-22
5. Gascon M.P., and Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur. J. Clin. Pharmacol. 41 (1991) 573-578
6. Greenblatt D.J., Preskorn S.H., Cotreau M.M., Holst W.D., and Harmatz J.S. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin. Pharmacol. Ther. 52 (1992) 479-486
7. Guengerich F.P., Muller-Enoch D., and Blair I.A. Oxidation of quinidine by liver cytochrome P-450. Mol. Pharmacol. 30 (1986) 287-295
8. Harris J.W., Rahman A., Kim B.R., Guengerich F.P., and Collins J.M. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54 (1994) 4026-4035
9. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., and Cantilena L.R. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA, J. Am. Med. Assoc. 269 (1991) 1513-1518
10. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47 9 (1994) 1469-1479
11. Olkksola K.T., Aranko K., Luurla H., Hiller A., Saarnivaara L., Himberg J.J., and Neuvonen P.J. A potentially hazardous interaction between erythromycin and midazolam. Clin. Pharmacol. Ther. 53 (1993) 298-305
12. Olkkola K.T., Backman J.T., and Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55 (1994) 481-485
13. Rahman A., Korzekwa K.R., Grogan J., Gonzalez F.J., and Harris J.W. Selective biotransformation of taxol to 6;ga-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54 (1994) 5543-5546
14. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Harmatz J.S., and Shader R.I. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptakeinhibitor antidepressants, ketoconazole and quinidine. Br. J. Clin. Psychopharmacol. 38 (1994) 23-31
15. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Duan S.X., Harmatz J.S., and Shader R.I. Inhibition of desipramine hydroxylation in vitro by serotoninreuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 268 3 (1994) 1278-1283
16. von Moltke L.L., Greenblatt D.J., Court M.H., Duan S.X., Harmatz J.S., and Shader R.I. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 15 (1995) 125-131
17. Wrighton S.A., and Ring B.J. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharma. Res. 11 6 (1994) 921-924
18. Yun C.H., Okerholm R.A., and Guengerich F.P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Drug Metab. Dispos. 21 3 (1993) 403-409